APOH抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: Human testis tissue, Primary antibody: P07117(APOH Antibody) at dilution 1/275, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P07117(APOH Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P07117(APOH Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

APOH antibodies, also called anti-β2-glycoprotein I (β2GPI) antibodies, are autoantibodies targeting apolipoprotein H (APOH), a plasma protein involved in lipid metabolism and blood clotting regulation. Discovered in the 1990s, these antibodies are strongly associated with antiphospholipid syndrome (APS), a disorder characterized by recurrent thrombosis, pregnancy complications, and persistent antiphospholipid antibodies. Unlike antibodies to cardiolipin or lupus anticoagulants, APOH antibodies specifically recognize epitopes on β2GPI, a cofactor required for binding anionic phospholipids.

In APS, APOH antibodies disrupt β2GPI’s anticoagulant function by forming immune complexes that activate endothelial cells, platelets, and complement pathways, promoting thrombosis. They are considered more specific than other antiphospholipid antibodies for diagnosing APS, particularly in thrombotic events and obstetric complications like recurrent miscarriages. Elevated APOH antibodies are also observed in autoimmune diseases (e.g., SLE) and infections, though transiently. Testing involves ELISA, with IgG/IgM isotypes having higher clinical relevance. Research continues to explore their pathogenic mechanisms, including interactions with coagulation factors and cellular receptors, to improve diagnostic accuracy and targeted therapies.